Computational models for tissue engineering

One of the major challenges in tissue engineering is the translation of biological knowledge on complex cell and tissue behavior into a predictive and robust engineering process. Mastering this complexity is an essential step towards clinical applications of tissue engineering. In order to tackle these issues, researchers at GIGA are developping computational models that can help in:

  • Quantifying and optimizing the tissue engineering product, e.g. by adapting scaffold design to optimize micro-environmental signals or by adapting selection criteria to improve homogeneity of the selected cell population
  • Quantifying and optimizing the tissue engineering process, e.g. by adapting bioreactor design to improve quality and quantity of the final product
  • Assessing the influence of the in vivo environment on the behavior of the tissue engineering product, e.g. by investigating vascular ingrowth

Interested in these projects? Drop us an email [info@b2h.be]. We are looking forward collaborating with you!

Model-based therapeutics

By combining mathematical models and experimental and/or clinical data, we have built “virtual patients”. A virtual patient represents a specific patient in a particular state relative to the system modeled (e.g. metabolic, cardiovascular, pulmonary and musculoskeletal).

These virtual patients are useful to:

  • Implement bedside decision-support clinical systems
  • Safely and rapidly design, prototype and optimize treatment protocols
  • Optimize glycemic control and mechanical ventilation strategies in critically ill patients
  • Propose innovative therapeutic solutions to bone fractures in patient with genetic diseases and experiencing healing difficulties

Interested in these projects? Drop us an email [info@b2h.be]. We are looking forward collaborating with you!

Biomarker discovery platform

We acquired a solid expertise in the field of clinical proteomics for biomarker and the discovery of new therapeutic targets in many types of biological matrices (plasma, serum, synovial fluids and tissues [biopsies, FFPE tissue sample]). We focus on rheumatic diseases (osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, pseudarthrosis).

We can provide complete proteomics solution for companion biomarker discovery and validation. The analysis and study design are applied by experts in the fields of proteomic data interpretation and with a critical view of the clinical and pathological context. This multidisciplinary team of experts can help to speed up research project and to gain further knowledge about clinical trial sample cohorts.

Interested in these projects? Drop us an email [info@b2h.be]. We are looking forward collaborating with you!

Selective glucocorticoid receptor agonists

Glucocorticoids (GC) are potent anti-inflammatory drugs widely used to induce remission in rheumatoid arthritis or to treat an acute flair-up in osteoarthritis.

Unfortunately, GC contribute to adverse events giving rise to metabolic syndromes such as diabetes and weight gain, leading sometimes to a high morbidity. Accordingly, we focus on new molecules, namely selective glucocorticoid receptor agonists (SEGRAs), with a better benefit/risk ratio compared to GC. Anti-inflammatory and anti-metabolic properties of SEGRAs are evaluated in vitro on human joint cells.

Interested in these projects? Drop us an email [info@b2h.be]. We are looking forward collaborating with you!